Index

Abrams, Richard, 7
N-acetylcysteine, 251
acupuncture, 204
addictive behaviour
stages of change, 156–57
affective instability
distinction from hypomania,
83–84
in BPD, 81–83
agomelatine, 215
alcohol problems, 154–55
alpha-linolenic acid, 133–34, 136,
139
Altman Self-Rating Mania Scale
(ASRM), 75, 197
Alzheimer’s disease, 133, 138, 248
amphetamine, 239
anger and bipolar disorder,
147–48
anger management techniques,
147–48
Angst, Jules, 6
antidepressant therapy, 100–10,
228–30, 254–55, 259
and anxiety disorders in BP
II, 101
and substance use disorders,
101
and suicidality, 105
bipolar spectrum perspective,
25–26
co-administration with mood
stabilisers in BP II, 108–09
controversy over, 271–73
defining the pathology,
100–02
delineating the clinical status,
100–02
depression with anxiety in BP
II, 102
differential diagnosis of BP II,
100–02
dosing in BP II, 109
efficacy in BP II depression,
105–07
efficacy in relapse prevention,
107
efficacy of, 248–49
impact on recurrence in BP II,
109–10
kindling effect, 29–30
long-term destabilisation,
29–30
long-term effects in BP II, 232
loss of antidepressant efficacy,
109
mixed hypomania vs. pure
depression in BP II, 102–03
mood destabilisation concerns,
104–05, 232
novel antidepressants, 274
‘poop-out’ phenomenon,
109
possible novel antidepressants,
107–08
questionable efficacy in BP II,
231–32
role in management of BP II,
110
safety concerns,
26–30
special features of BP II,
273–74
views on the use of, 273–74
attention deficit hyperactivity
disorder (ADHD), 44, 49,
57–58
atypical antipsychotic drugs,
126–30
olanzapine, 129
quetiapine, 127–28
risperidone, 128
side-effects, 27
special features of BP II,
126–27
use in the treatment of BP II,
127
atypical depression, 82
Baillarger, Jules, 3
Ban, Thomas, 4
behavioural disorders
association with BP II, 58
biological causes of mood
disorders, 16
bipolar depression
diagnosis and treatment,
126–27
treatment challenges, 216
bipolar II disorder
clinically meaningful category,
266
Bipolar Spectrum Diagnostic
Scale (BSDS), 18–19, 22
bipolar spectrum perspective,
10–32
and treatment options, 25–26
antidepressant efficacy, 25–26
antidepressant safety concerns,
26–30
Bipolarity Index, 19–21
compared to categorial
perspective, 10–11
dealing with comparative risks,
30–31
degree of mania present, 17
diagnostic implications,
17–25
diagnostic perspective, 10–11
improving public awareness
and understanding, 21–22
limitations of the DSM
approach, 15–19
mixed states, 14–15
partial solutions to DSM
limitations, 19–25
reviews, 10
soft bipolarity, 11–14
sub-threshold bipolarity, 12
supporting evidence, 11–12
teaching patients and families
about BP II, 22–25
treatment implications, 25–31
use alongside categorical
models, 31–32
Bipolarity Index, 19–21
aid to communication, 20–21
decreasing diagnosis rejection, 21
dimensions, 19
expansion of the diagnostic
process, 20
practicality, 19–20
Black Dog Institute questionnaire
development, 37–43
Black Dog Institute studies
personality and BP II, 74–77
prevalence of BP II, 65–67
temperament and BP II, 74–77
Borderline Personality Disorder
(BPD), 44, 51, 121, 217
affective instability, 81–83
distinction from BP II, 81–85
features of, 81–83
brain-derived neurotrophic factor
(BDNF), 93, 138, 248
British Prime Ministers
possible BP II diagnoses, xii
bupropion, 104–06, 216, 249, 251, 255
Canadian Network for Mood
and Anxiety Treatments
(CANMAT) guidelines, 127
carbamazepine, 114, 120–21, 138,
199, 200, 216, 233, 248, 250, 255
cardiocascular disease, 133, 138
cardiocvascular risk
medication side-effect, 27
Carroll, Bernard, 7
categorical model of BP II, 35–45
Black Dog Institute
questionnaire development,
37–43
clinical detection and screening,
43–44
distinguishing BP I and BP II,
35, 45
DSM system, 35–37
ICD-10 system, 37
self-testing for bipolar disorder,
44–45
cerebral blood flow in BP II, 90
cerebral glucose metabolism in
BP II, 90
Chiarugi, Vincenzo, 2
chronobiological interventions, 204
citalopram, 118
Clayton, Paula, 6
clinical model (Ketter and Wang)
adjunctive chronobiological
interventions, 204
adjunctive lithium, 203
adjunctive modafinil, 203
adjunctive nutricutical
interventions, 204
adjunctive pramipexole, 203
adjunctive psychotherapies,
204–06
antidepressant therapies,
202–03
interpolation from BP I and
unipolar MDD, 193
management of BP II, 192–208
measurement, 196–97
mood stabilisers, 199–200
multiphase management
strategy, 192–93
neuromodulation interventions,
203
pharmacological sub-types of
BP II, 198–99
prescription psychotropic
medications, 198–99
psychoeducation, 194–96, 206
second-generation
antipsychotics, 200–02
self-assessment of mood
symptoms and side-effects,
196–97
somatic interventions, 197–204
well-being plans, 206–08
See also management
commentaries.
clinical model (Parker)
antidepressant therapies, 185–87
bipolar depression
management, 185–87
bipolar ‘highs’ or hypomania
management, 187
introducing a management
plan, 182–83
management of BP II, 182–91
medication strategies, 184–87
mood charting, 188–89
mood stabilisation, 184–85
non-drug management
components, 187–91
patient and family education, 188
providing a diagnosis, 182–83
psychotherapy, 190–91
well-being plan, 189–90
See also management
commentaries.
cognitive behaviour therapy
(CBT), 144, 206, 256
comorbidity associated with BP II,
50–51, 56–61, 217, 222
ADHD, 58
anxiety disorders, 57–58
behavioural disorders, 58
borderline personality disorder
(BPD), 51
BP II as risk factor for other
conditions, 59–60
compared to BP I, 59
conditions which increase risk
of BP II, 60–61
definition of comorbidity,
56–57
diagnostic confounding, 58
eating disorders, 58
effects on clinical management,
61
higher-order risk factors, 61
impulse control disorders,
57–58
medical problems, 51
migraine headaches, 51
over-represented antecedents of
BP II, 59
possible models of ‘true’
comorbidity, 59–61
quantifying comorbid
conditions, 57–59
role of psychological
interventions, 148
substance abuse, 147
substance use disorders, 58
use of mood stabilisers, 121
comprehensive care management,
254
conduct disorder, 57
consequences of bipolar disorder,
145–46
creativity, 164
cyclothymia
ICD-10, 37
origin of the term, 3–4
cyclothymic disorder, 218
D Club story of personal experience, xi–xv
decision-making with incomplete data, 245–46
deep brain stimulation, 203
defining BP II
Black Dog Institute questionnaire, 37–43
categorical model, 35–45
clinical detection and screening, 43–44
distinguishing BP I and BP II, 35, 45
DSM system, 35–37
ICD-10 system, 37
self-testing for bipolar disorder, 44–45
depression
health risks of recurrent depressive illness, 247–48
Depression and Bipolar Support Alliance (DBSA), 195
depression with anxiety in BP II antidepressant therapy, 102
desvenlafaxine, 104, 186
dextroamphetamine, 108
diabetes risk
medication side-effect, 27
diagnosis of BP II, 267–69
Black Dog Institute questionnaire, 37–43
categorical model, 35–45
changes in DSM-V, 221–22, 228
clinical detection and screening, 43–44
decreasing diagnosis rejection, 21
diagnostic boundaries, 219–20
distinguishing BP I and BP II, 35, 45
DSM system, 35–37
effects of personality and temperament, 77–78
ICD-10 system, 37
mnemonics, 20
Mood Disorder Questionnaire (MDQ), 42–43
Mood Swings Questionnaire (MSQ) development, 37–43
need for professional awareness, xii
over- and under-diagnosis, xi–xii
providing a diagnosis, 182–83
self-testing for bipolar disorder, 44–45
training of health professionals, xi–xii
under-recognition of hypomania, 221–258
validity and reliability of, 258
dialectical behaviour therapy (DBT), 222
dietary change
production of inflammatory eicosanoids, 133–34
differential diagnosis for BP II, 81–85, 237–39
affective instability in BPD, 81–82, 83
Borderline Personality Disorder (BPD), 81–85
features of BPD, 81–83
hypomania vs. affective instability, 83–84
implications for treatment, 85
obstacles to accurate diagnosis, 84–85
psychiatric diagnosis, 81
DIGFAST diagnostic mnemonic, 20
disability associated with BP II, 49–50
docosahexaenoic acid (DHA), 133–34, 137–39, 204
Dragun, Charmaine, xii
drug problems, 154–55
drug-induced mixed states, 220–21
DSM (Diagnostic and Statistical Manual) (APA), 7
DSM system, 35–37
bipolar spectrum perspective, 15–17
DSM-V, 36, 47, 126
diagnostic changes for BP II, 221–22, 228
mixed states, 15
DSM-III, 7
DSM-IV, 75
BP II criteria, 46, 194
mixed states, 14–15
duloxetine, 104, 255
dysphoric hypomania, 247
Dysphthia atra, 3
Dysphthia candida, 3
Dysphthia mutabilis, 3
earlier detection interventions, 227
eating disorders
association with BP II, 58
economic burden of bipolar disorders, 52–53
eicosapentaenoic acid (EPA), 133–34, 137–39, 204
electroconvulsive therapy, 203, 216, 259
emotional dysregulation in BPD.
See affective instability in BPD epidemiological studies
fish consumption and mood disorders, 134–35
prevalence of BP II, 63–65
epidemiology of BP II, 47–49
escit洛xapram, 106–07, 215, 239
Esquirol, Etienne, 1
explosive personality style, 44
Eysenck Personality Inventory (EPI), 71
Falret, Jean-Pierre, 3
family-focused therapy (FFT), 144–45, 206, 256
family member involvement, 241
Feighner criteria, 6
Fink, Max, 7
fish oil
biological marker studies, 135
clinical use, 184–85
dietary changes in fatty acid intake, 133–34
efficacy of, 241
epidemiological studies, 134–35
features of N-3 PUFAs, 133
history of N-3 PUFAs, 133–34
mood disorder treatment studies, 135–37
N-3 PUFAs and mood disorders, 137–38
N-3 PUFAs and switching, 137
neuroscientific mechanisms of action, 137–38
omega-3 fatty acids, 133
potential treatment recommendations, 138–39
public health issues, 134
research studies, 134–37
role in BP II management, 133–40
Five Factor Model (FFM) of personality, 75–76
Flemming, Carl Friedrich, 3
fluoxetine, 106–07, 201, 239, 259
folate, 204, 251
Frequency and Intensity of Burden of Side Effects Rating, 197
frustration management techniques, 147–48
future history of Bipolar II disorder, 262–65
gabapentin, 114, 118–19, 121, 251
Gallop, Geoff, xiv
generalised anxiety disorder (GAD), 51, 57
genetics of BP II, 95
genetics of mood disorders, 16
glial-derived neurotrophic factor (GDNF), 93
glutamate antagonists, 108
group work, 146–47
Hamilton Depression Scale (HAM-D), 106, 136
Hamilton Rating Scale for Anxiety (HAMA), 128
Hamilton Rating Scale for Depression (HAMD), 128
Hecker, Ewald, 46
Heinroth, Johann Christian, August, 2–3
historical perspective
alternation of mania and melancholia, 1–2
cyclothymia, 3–4
Diagnostic and Statistical Manual (DSM) (APA), 7
earliest descriptions of bipolar disorder, 2–4
hypomania, 4
Kraepelin's classification of psychiatric illness, 4–5
mania, 1
manic-depression, 1
melancholia, 1
multipolar disorder (Swartz), 1
periodic and cyclic psychoses (Leonhard), 5–6
recognition of bipolar disorders, 1–8
Research Diagnostic Criteria (RDC), 6–7
separation of depressions by polarity, 5–6
terminality, 1
unipolar and bipolar depressions, 5–6
homeopathy, 204
hyperglycaemia
medication side-effect, 27
hypomania, 126
antidepressant-induced, 103
diagnostic criteria, 219–20
disagreement over definition, 46–47
distinction from affective instability, 83–84
dysphoric, 247
mixed hypomania versus pure depression in BP II, 102–03
origin of the term, 4
under-recognition in diagnosis, 221–22
hypomania management
role of mood stabilisers, 115–16
hypothyroidism
lithium side-effect, 25
ICD-10 system, 37
imipramine, 107, 117
impulse control disorders
association with BP II, 57–58
inflammatory conditions, 248
inflammatory eicosanoids pathological consequences, 133–34, 137–38
inositol, 118, 204
intermittent explosive disorder, 57
interpersonal and social rhythm therapy (IPSRT), 145, 206, 256
Inventory for Depressive Symptoms (IDS), 108
Kahlbaum, Karl, 3–4
Kaulbaum, Ludwig, 46
ketamine, 108, 251, 259
kindling effect, 138
and antidepressants, 29–30
Kern, Ludwig, 3
Klein, Gary, 245–46
Kleist, Karl, 5
Kraepelin, Emil, 4–5, 46
la folie à double forme, 3
la folie circulaire, 3
See also mood stabilisers.
Leonhard, Karl, 5–7
Life Goals Collaborative Care programme, 207–08
lifestyle factors in BP II, 223–24
light therapy, 204, 251
liothyrone, 203, 216, 242
See also mood stabilisers.
long-term prophylaxis, 247–48, 251–52
management approaches
clinical model (Ketter and Wang), 192–208
clinical model (Parker), 182–91
See also management commentaries; management of BP II
management commentaries
access to psychoeducational programmes, 236
alternatives to antidepressant therapy, 249–51
antidepressant therapy, 228–32, 248–49, 251, 254–55, 259
antidepressant-induced rapid cycling, 221
antidepressants and stage of illness, 233
anxiety in bipolar disorder, 243
challenges of bipolar depression, 216
clinical decision-making, 245–46
comorbidity, 217, 222
comprehensive care management, 254
cyclothymic disorder, 218
decision-making with incomplete data, 245–46
diagnostic boundaries in BP II, 219–20
diagnostic changes and implications, 221–22
diagnostic criteria, 199–200
duration of pharmacotherapy, 239–40
earlier detection interventions, 227
effective use of neuroleptics, 232
family member involvement, 241
future history of Bipolar II disorder, 262–65
drug-induced rapid cycling, 221
drug-induced mixed states, 220–21
drug-induced mixed states
,long-term prophylaxis, 247–48, 251–52
management approaches
clinical model (Ketter and Wang), 192–208
clinical model (Parker), 182–91
See also management commentaries; management of BP II
management commentaries
access to psychoeducational programmes, 236
alternatives to antidepressant therapy, 249–51
antidepressant therapy, 228–32, 248–49, 251, 254–55, 259
antidepressant-induced rapid cycling, 221
antidepressants and stage of illness, 233
anxiety in bipolar disorder, 243
challenges of bipolar depression, 216
clinical decision-making, 245–46
comorbidity, 217, 222
comprehensive care management, 254
cyclothymic disorder, 218
decision-making with incomplete data, 245–46
diagnostic boundaries in BP II, 219–20
diagnostic changes and implications, 221–22
diagnostic criteria, 199–200
duration of pharmacotherapy, 239–40
earlier detection interventions, 227
effective use of neuroleptics, 232
family member involvement, 241
future history of Bipolar II disorder, 262–65
management commentaries (cont.)
general principles for BP II
treatment, 258–60
health risks of recurrent
depressive illness, 247–48,
251–52
hypomania diagnostic
criteria, 219–20
importance of long-term
prophylaxis, 247–48, 251–52
initial treatment, 232–33
lack of BP II treatment studies,
258
lack of clinical trial data, 224
lifestyle factors in BP II, 223–24
long-term effects of
antidepressants, 232
management strategies, 214–16
management strategy, 223
memories of bipolar individuals,
235–36
mixed states in BP II, 220–21
mood charting, 235, 243, 251
mood destabilisation by
antidepressants, 232
mood stabilisers, 255–56, 259
non-drug interventions, 216,
242–43
patient autonomy, 246
patient education about health
risks, 247–48, 251–52
patient sub-types of BP II,
226–27
pharmacological algorithms,
234–35
pharmacological management,
228–30, 241–42
pharmacotherapy options, 239
phrenosis and clinical common
sense, 245–46
presentation of BP II illness, 214
psychoducation, 215, 228,
242–43, 259–60
psychosocial strategies, 235–36
psychostimulants, 239
psychotherapy, 215, 240, 243,
256, 259–60
recurrence prevention, 231–32
role of significant others, 214
second-generation
antipsychotics, 256
staging of illness, 222–24
suicidal behaviour, 217
therapeutic alliance, 226
under-recognition of
hypomania, 221–22
use of low-dose mood
stabilisers, 232–33
validity and reliability of BP II
diagnosis, 258
variability in clinical and
functional outcomes, 226–27
web-based educational tools,
228
web-based psychoeducational
programmes, 236
management of BP II
compared to BP I, 270
effects of comorbidities, 61
evidence base and clinical
experience, 271
future directions, 274–75
non-drug management
strategies, 270–71
variability of views and
interpretations, 274–75
See also well-being plan.
melancholia
history of the term, 1
manic-depression
history of the term, 1
Maudsley Personality Inventory,
72
Measurement Based Care, 254
measuring BP II, 267–69
Black Dog Institute
questionnaire, 37–43
categorical model, 35–45
diagnostic criteria, 43–44
distinguishing BP I and BP II,
35, 45
DSM system, 35–37
ICD-10 system, 37
self-testing for bipolar disorder,
44–45
medication adherence
psychological interventions, 146
melancholia
history of the term, 1
melancholia attonita, 3
memories of bipolar individuals,
235–36
Mendel, Emanuel Ernst, 4
methylphenidate, 108, 186, 239,
242
migraine headaches
association with BP II, 51
milnacipran, 104
mindfulness techniques, 164
mindfulness-based
psychotherapies, 216
Mini International
Neuropsychiatric Interview
(MINI), 12, 75–76
mirtazapine, 104, 186, 216
mixed states, 220–21
antidepressant-induced, 28
spectrum perspective, 14–15
moclobemide, 106
modafinil, 107–08, 203, 239, 242,
251, 259
modelling BP II
bipolar spectrum perspective,
10–32
categorical model, 35–45
clinical model (Ketter and
Wang), 192–208
clinical model (Parker),
182–91
need for a more valid model,
266–67
monoamine oxidase inhibitors
(MAOIs), 104–06
Montgomery, Katherine, 182,
245, 271
Montgomery–Åsberg Depression
Rating Scale (MADRS),
128
Mood Assessment Program
(MAP), 76
mood charting, 188–89, 243, 251
concerns about, 235
mood destabilisation
associated with antidepressants,
104–05, 232
Mood Disorder Questionnaire
(MDQ), 18–19, 47, 58
comparison with MSQ, 42–43
mood stabilisers, 114–22, 184–85,
199–200, 215, 248, 253–56,
259
counteraction by
antidepressants, 232
definitions, 114
low-dose initial treatment,
232–33
management of acute
depression, 116–19
management of hypomania,
115–16
rates of use in BP II patients,
114
role in BP II maintenance
therapy, 119–22
role in BP II management,
114–15
views on the use of, 273
Index

psychological interventions (cont.)
BP II management issues
addressed, 143
consequences of bipolar disorder, 145–46
factors in maintaining good functioning, 148
finding the right psychotherapist, 148–49
for comorbid anxiety, 148
for comorbid personality disorder, 148
for comorbid substance abuse, 148
for substance abuse, 147
for violent behaviour, 147–48
frustration management techniques, 147–48
individual stay well plans, 148
interpersonal and social rhythm therapy (IPSRT), 145
medication adherence, 146
pluralistic approach to BP II management, 142
practical issues, 148–49
psychoeducation, 144
psychosocial factors in mood disorders, 142
range of interventions for bipolar disorder, 143
role in long-standing BP II, 143
stress-vulnerability models, 142
therapeutic alliance, 143–44
timing of interventions, 142
treatment efficacy, 147
well-being plan, 143
See also cognitive behaviour therapy (CBT); family-focused therapy (FFT).
psychosocial factors in mood disorders, 142
psychosocial strategies in BP II, 235–36
psychostimulants, 239, 251
psychotherapy, 190–91, 204–06, 215, 240, 243, 256–260
public education, 22
quetiapine, 22, 27, 116, 117, 127, 201, 216, 242, 250, 256, 259
BP II treatment studies, 127–28
Quick Inventory of Depressive Symptoms – Self-Report (QIDS-SR), 75, 197
rapid cycling
antidepressant-induced, 28, 104, 221
Research Diagnostic Criteria (RDC), 6–7
riluzole, 108
risperidone, 118, 201–02, 259
BP II treatment studies, 128
Robins, Eli, 7
SAME (S-adenosyl-l-methionine), 204
schizophrenia, 126
Schneider, Carl, 246
Schwartz, Barry, 245
scolopamine, 251
second-generation antipsychotics, 200–02, 256
selective serotonin reuptake inhibitors (SSRIs), 102, 104, 106–07, 184–86, 189, 215, 239, 241–42, 251, 255
selegeline, 106
self-assessment of mood symptoms and side-effects, 196–97
self-change stages, 156–57
maintenance stage, 119–22
self-testing for bipolar disorder, 44–45
serotonin-norepinephrine reuptake inhibitors (SNRIs), 184, 186, 216, 241–42, 251
sertraline, 104, 106, 249
Sharpe, Richard, 245
significant others
role in BP II management, 214
diagnoses, 74
sleep deprivation interventions, 204, 251
sleep disorders, 217
Social and Occupational Functioning Assessment Scale (SOFAS), 107
social phobia, 57
soft bipolarity, 13–14, 35
spectrum perspective. See bipolar spectrum perspective
Spiegelber State-Trait Anxiety Inventory, 75
Spitzer, Robert, 6–7
St John’s wort (Hypericum perforatum extract), 204
states of change, 156–57
staging of illness, 222–24
Stevens–Johnson syndrome, 27
stress-vulnerability models, 142
Structured Clinical Interview for DSM-IV (SCID), 48
substance abuse
and bipolar disorder, 148
and violence, 147
substance use disorders
and antidepressant therapy, 101
association with BP II, 58
sub-types of BP II, 198–99,
226–27, 267–69
suicidal behaviour, 255
and antidepressants, 105
lithium therapy, 117, 119–20
management of, 217
suicide
case of Charmaine Dragun, xii
suicide risk
and antidepressants, 102
and psychological interventions, 147
associated with BP II, xii, 49–50
in depressive illness, 247
Swartz, Conrad, 1
T, 216, 251
tardive dyskinesia, 27
tardive dysphoria states, 30
Taylor, Michael, 6, 7
temperament and BP II
Black Dog Institute studies, 74–77
BP I comparisons, 74
comparison with BP I and unipolar depression, 70
defining and measuring temperament, 71–72
diagnostic implications, 77–78
healthy control comparisons, 73–74
methodological considerations, 71
T&P profiles, 75–77
unipolar comparisons, 74
Temperament and Character Inventory (TCI), 72
Temperament and Personality Questionnaire (T&P), 75–77
Temperament Evaluation of the Memphis, Pisa, Paris and San Diego Questionnaire (TEMPAS), 72
therapeutic alliance, 215, 226
topiramate, 114, 119, 121, 138, 251
transcranial magnetic stimulation, 203, 216
transthyretin, 104, 242
treatment-emergent affective switch (TEAS), 199, 202, 204, 239
tricyclic antidepressants, 255
Tri-dimensional Personality Questionnaire, 72
vagus nerve stimulation, 203
valproate, 22, 27, 107, 138, 184, 199, 200, 216, 232, 241, 248, 250, 255
See also mood stabilisers.
venlafaxine, 104, 106, 117, 249, 255
violence
psychological interventions, 147–48
web-based educational tools, 228
web-based psychoeducational programs, 236
weight gain
medication side-effect, 27
well-being plan, 143, 148, 151–57, 189–90, 206–08
drug and alcohol problems, 154–55
key secrets for managing bipolar disorder, 163
knowledge about the illness, 151–52
motivation to commit to, 152–54
motivational interviewing for bipolar disorder, 155–56
need for self-monitoring, 151–52
needs to fit the person, 163
recognising the need for, 152–54
stages of change, 156–57
taking steps to manage your illness, 151–52
well-being plan creation, 157–65
acknowledge difficulty of receiving feedback, 161
aim for stages of recovery, 162–63
benefits of collaboration, 163–64
commitment to personal growth, 164
debrief past efforts by others to help, 158–59
don't aim too low for too long, 162–63
dynamic, lifestyle-enriching strategies, 164
earliest possible intervention, 161
how feedback will be delivered, 161
identify early warning signs, 159–60
identify risk factors and triggers, 160–61
making creativity work, 164
meaning of recovery, 164–65
mindfulness techniques, 164
positive psychology approach, 165
quality-of-life activities, 162
quality-of-life matters, 164
specify safety measures, 161–62
strengths and weaknesses of close relationships, 162
Wernicke, Carl, 5
Winokur, George, 6
Young Mania Rating Scale (YMRS), 103, 106, 136
ziprasidone, 129, 201, 256